Literature DB >> 16012179

Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer.

M Moroni, A Sartore-Bianchi, S Benvenuti, S Artale, A Bardelli, S Siena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16012179     DOI： 10.1093/annonc/mdi356

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.

Authors:  Eunice L Kwak; Janusz Jankowski; Sarah P Thayer; Gregory Y Lauwers; Brian W Brannigan; Patricia L Harris; Ross A Okimoto; Sara M Haserlat; David R Driscoll; David Ferry; Beth Muir; Jeff Settleman; Charles S Fuchs; Matthew H Kulke; David P Ryan; Jeff W Clark; Dennis C Sgroi; Daniel A Haber; Daphne W Bell
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

2.  Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

Authors:  Ian J Majewski; René Bernards
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

Review 3.  Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?

Authors:  M Ponz-Sarvisé; J Rodríguez; A Viudez; A Chopitea; A Calvo; J García-Foncillas; I Gil-Bazo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 4.  Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.

Authors:  Hui-Yan Luo; Rui-Hua Xu
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

5.  A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.

Authors:  El Mustapha Bahassi; Ya-Qin Li; Trisha M Wise-Draper; Li Deng; Jiang Wang; Colleen N Darnell; Keith M Wilson; Susanne I Wells; Peter J Stambrook; Olivier Rixe
Journal:  Eur J Cancer       Date:  2013-04-08       Impact factor: 9.162

6.  Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.

Authors:  Rossana Berardi; Azzurra Onofri; Mirco Pistelli; Elena Maccaroni; Mario Scartozzi; Chiara Pierantoni; Stefano Cascinu
Journal:  Core Evid       Date:  2010-10-21

Review 7.  Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

Authors:  Tomoya Yokota
Journal:  Anticancer Agents Med Chem       Date:  2012-02       Impact factor: 2.505

Review 8.  Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Authors:  Salvatore Siena; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Julia Balfour; Alberto Bardelli
Journal:  J Natl Cancer Inst       Date:  2009-09-08       Impact factor: 13.506

9.  The genomic landscape of response to EGFR blockade in colorectal cancer.

Authors:  Andrea Bertotti; Eniko Papp; Siân Jones; Vilmos Adleff; Valsamo Anagnostou; Barbara Lupo; Mark Sausen; Jillian Phallen; Carolyn A Hruban; Collin Tokheim; Noushin Niknafs; Monica Nesselbush; Karli Lytle; Francesco Sassi; Francesca Cottino; Giorgia Migliardi; Eugenia R Zanella; Dario Ribero; Nadia Russolillo; Alfredo Mellano; Andrea Muratore; Gianluca Paraluppi; Mauro Salizzoni; Silvia Marsoni; Michael Kragh; Johan Lantto; Andrea Cassingena; Qing Kay Li; Rachel Karchin; Robert Scharpf; Andrea Sartore-Bianchi; Salvatore Siena; Luis A Diaz; Livio Trusolino; Victor E Velculescu
Journal:  Nature       Date:  2015-09-30       Impact factor: 49.962
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.